Oncolytics Biotech (ONCY) Share-based Compensation (2009 - 2025)

Oncolytics Biotech (ONCY) has reported Share-based Compensation for 17 consecutive years, with $3.0 million the latest figure, recorded in Q3 2025.

• On a quarterly basis, Share-based Compensation rose 817.29% year-over-year to $3.0 million in Q3 2025; TTM through Sep 2025 was $5.1 million, a 201.45% increase from a year earlier, with the FY2025 full-year figure at $3.5 million, up 74.92% from the prior year.
• Share-based Compensation was $3.0 million for Q3 2025 at Oncolytics Biotech, up from $377455.6 in the prior quarter.
• Over five years, Share-based Compensation peaked at $3.0 million in Q3 2025 and troughed at $180157.5 in Q2 2023.
• A 5-year average of $657342.5 and a median of $504474.8 in 2022 frame the typical range for Share-based Compensation.
• Across the five-year window, Share-based Compensation slumped 54.22% in 2022 and jumped 817.29% in 2025, its largest moves.
• Over 5 years, Share-based Compensation stood at $895487.6 in 2021, then sank by 38.38% to $551790.5 in 2022, then increased by 1.04% to $557512.5 in 2023, then jumped by 53.57% to $856155.6 in 2024, then jumped by 249.5% to $3.0 million in 2025.
• The last three Share-based Compensation figures came in at $3.0 million (Q3 2025), $377455.6 (Q2 2025), and $841875.1 (Q1 2025), per Business Quant data.